Nanovectors for anti-cancer drug delivery in the treatment of advanced pancreatic adenocarcinoma

doi:10.3748/wjg.v22.i31.7080

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 22, Issue 31

This Article

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (10517)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-2) series.

Item

Count

PDF

889

WORD

411

HTML

5696

Tables (1-2)

454

Sum=7450

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1340

Download

1726

Sum=3066

Aug 21, 2016 (publication date) through Feb 27, 2026

Times Cited of This Article

Times Cited (10)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Minireviews

World J Gastroenterol. Aug 21, 2016; 22(31): 7080-7090
Published online Aug 21, 2016. doi: 10.3748/wjg.v22.i31.7080

Nanovectors for anti-cancer drug delivery in the treatment of advanced pancreatic adenocarcinoma

Chung-Tzu Hsueh, Julie H Selim, James Y Tsai, Chung-Tsen Hsueh

Chung-Tzu Hsueh, Department of Dentistry, Cathay General Hospital, Taipei 10630, Taiwan

Julie H Selim, Division of Hematology/Oncology, Loma Linda University Cancer Center, Loma Linda, CA 92350, United States

Julie H Selim, School of Pharmacy, Loma Linda University, Loma Linda, CA 92350, United States

James Y Tsai, Chung-Tsen Hsueh, Division of Medical Oncology and Hematology, Department of Internal Medicine, Loma Linda University, Loma Linda, CA 92354, United States.

Author contributions: Hsueh CT, Selim JH, Tsai JY and Hsueh CT conceived the issues which formed the content of the manuscript and wrote the manuscript.

Conflict-of-interest statement: The authors have no conflict of interest to report.

Correspondence to: Chung-Tsen Hsueh, MD, PhD, Division of Medical Oncology and Hematology, Department of Internal Medicine, Loma Linda University, 11175 Campus Street, CSP 11015, Loma Linda, CA 92354, United States. chsueh@llu.edu

Telephone: +1-909-5588107 Fax: +1-909-5580219

Received: March 30, 2016
Peer-review started: April 6, 2016
First decision: May 30, 2016
Revised: June 13, 2016
Accepted: July 6, 2016
Article in press: July 6, 2016
Published online: August 21, 2016
Processing time: 137 Days and 17.3 Hours

Abstract

Liposome, albumin and polymer polyethylene glycol are nanovector formulations successfully developed for anti-cancer drug delivery. There are significant differences in pharmacokinetics, efficacy and toxicity between pre- and post-nanovector modification. The alteration in clinical pharmacology is instrumental for the future development of nanovector-based anticancer therapeutics. We have reviewed the results of clinical studies and translational research in nanovector-based anti-cancer therapeutics in advanced pancreatic adenocarcinoma, including nanoparticle albumin-bound paclitaxel and nanoliposomal irinotecan. Furthermore, we have appraised the ongoing studies incorporating novel agents with nanomedicines in the treatment of pancreatic adenocarcinoma.

Keywords: Pancreatic adenocarcinoma; Nanovector; Nanoparticle albumin-bound paclitaxel; Nanoliposomal irinotecan; Biomarker

Core tip: The nanovector-based anti-cancer therapeutics play important role in the treatment of advanced pancreatic adenocarcinoma. Data from completed clinical trials are reviewed, and important ongoing studies are presented. Biomarkers for patient selection and personalized medicine are discussed.